Covered recipient · General Payments record
ASHLEY CAUTHEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$34,755.77
142 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,100.50 | 11 |
| Food and Beverage | $3,466.90 | 123 |
| Travel and Lodging | $2,492.92 | 6 |
| Consulting Fee | $1,612.50 | 1 |
| Education | $82.95 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $30,230.68 | 26 |
| E.R. Squibb & Sons, L.L.C. | $1,957.64 | 14 |
| ABBVIE INC. | $409.90 | 12 |
| Janssen Biotech, Inc. | $289.70 | 8 |
| UCB, Inc. | $242.45 | 13 |
| Regeneron Healthcare Solutions, Inc. | $234.56 | 9 |
| Dermavant Sciences, Inc. | $202.34 | 7 |
| Galderma Laboratories, L.P. | $169.03 | 10 |
| PFIZER INC. | $168.26 | 9 |
| Novartis Pharmaceuticals Corporation | $164.06 | 11 |
| Incyte Corporation | $140.56 | 3 |
| STRATA Skin Sciences, Inc. | $136.82 | 4 |
| Lilly USA, LLC | $97.71 | 2 |
| Arcutis Biotherapeutics, Inc. | $94.44 | 5 |
| LEO Pharma Inc. | $81.33 | 4 |
| Merz North America, Inc. | $52.23 | 1 |
| Sun Pharmaceutical Industries Inc. | $40.13 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.96 | 1 |
| Verrica Pharmaceuticals Inc. | $18.97 | 1 |
Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ASHLEY CAUTHEN
NPI 1720254071 · CMS profile ID 1307330
Allopathic & Osteopathic Physicians / Dermatology
OCALA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1720254071?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720254071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720254071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- ASHLEY CAUTHEN, NPI 1720254071, CMS profile ID 1307330, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1720254071?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
142 matching records · $34,755.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–142 of 142.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $944.30 | 04/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020539971 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.22 | 04/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999115631 | CMS |
| PFIZER INC. | $13.88 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049680387 | CMS |
| Amgen Inc. | $99.36 | 04/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020539973 | CMS |
| Merz North America, Inc. | $52.23 | 04/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051011977 | CMS |
| ABBVIE INC. | $21.46 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155391232 | CMS |
| AbbVie Inc. | $21.45 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996375337 | CMS |
| LEO Pharma Inc. | $18.37 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053460507 | CMS |
| Dermavant Sciences, Inc. | $16.92 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991168135 | CMS |
| AbbVie Inc. | $17.65 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996375335 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015753447 | CMS |
| PFIZER INC. | $21.37 | 04/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049228703 | CMS |
| Janssen Biotech, Inc. | $16.19 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988675665 | CMS |
| Novartis Pharmaceuticals Corporation | $27.41 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991825651 | CMS |
| UCB, Inc. | $5.77 | 03/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021791519 | CMS |
| Amgen Inc. | $3,738.00 | 03/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020816507 | CMS |
| Amgen Inc. | $623.00 | 03/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020816509 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7.25 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999115627 | CMS |
| UCB, Inc. | $29.03 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021791579 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015753399 | CMS |
| PFIZER INC. | $6.57 | 02/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049525533 | CMS |
| Amgen Inc. | $61.14 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020816505 | CMS |
| UCB, Inc. | $6.03 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021791531 | CMS |
| Novartis Pharmaceuticals Corporation | $13.61 | 02/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991825647 | CMS |
| Novartis Pharmaceuticals Corporation | $7.74 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991825644 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.83 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999115623 | CMS |
| PFIZER INC. | $3.94 | 02/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049543913 | CMS |
| AbbVie Inc. | $113.30 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996375333 | CMS |
| Dermavant Sciences, Inc. | $23.46 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991168131 | CMS |
| Galderma Laboratories, L.P. | $8.06 | 02/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059685783 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.46 | 02/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999115619 | CMS |
| PFIZER INC. | $45.77 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049621291 | CMS |
| PFIZER INC. | $24.66 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049111539 | CMS |
| Regeneron Healthcare Solutions, Inc. | $6.96 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999115615 | CMS |
| UCB, Inc. | $20.49 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021791557 | CMS |
| Janssen Biotech, Inc. | $16.91 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988675669 | CMS |
| Dermavant Sciences, Inc. | $137.24 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991168127 | CMS |
| Janssen Biotech, Inc. | $19.26 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988675667 | CMS |
| Amgen Inc. | $7.45 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020539963 | CMS |
| Galderma Laboratories, L.P. | $7.65 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059685781 | CMS |
| UCB, Inc. | $6.57 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021791545 | CMS |
| Novartis Pharmaceuticals Corporation | $14.16 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991825641 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,444.82 | 1 |
| PY2025 | Principal investigator | $782,109.75 | 232 |
| PY2024 | Recipient | $114.46 | 1 |
| PY2024 | Principal investigator | $614,925.76 | 288 |
| PY2023 | Principal investigator | $146,927.36 | 51 |
| PY2022 | Principal investigator | $211,308.04 | 59 |
| PY2021 | Recipient | $500.00 | 1 |
| PY2021 | Principal investigator | $442,861.62 | 55 |
| PY2020 | Recipient | $1,692.00 | 1 |
| PY2020 | Principal investigator | $453,418.14 | 69 |
| PY2019 | Recipient | $53,215.00 | 5 |
| PY2019 | Principal investigator | $1,449,298.77 | 93 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
233 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,742.00 | 12/19/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394485 |
| Principal investigator 1 | Incyte Corporation | $1,903.20 | 12/08/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582087 |
| Principal investigator 1 | Incyte Corporation | $7,850.00 | 12/04/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240582059 |
| Principal investigator 1 | Incyte Corporation | $1,800.00 | 12/04/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240582063 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 12/04/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240582067 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582079 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582083 |
| Principal investigator 1 | Incyte Corporation | $33.18 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582089 |
| Principal investigator 1 | Incyte Corporation | $49.77 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582093 |
| Principal investigator 1 | Incyte Corporation | $21.33 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582098 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582105 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582114 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,484.19 | 12/01/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289063 |
| Principal investigator 1 | Incyte Corporation | $1,808.80 | 11/24/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582071 |
| Recipient | Eli Lilly and Company | $2,444.82 | 11/10/2025 | Covered Recipient Physician | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE ATOPIC DERMATITIS AND HIGH ITCH BURDEN | No dispute reported | 06/30/2026 | 1187873827 |
| Principal investigator 1 | ABBVIE INC. | $6,804.53 | 11/05/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,871.00 | 11/03/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394540 |
| Principal investigator 1 | Eli Lilly and Company | $5,074.05 | 10/27/2025 | Non-covered Recipient Entity RENSTAR INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187888226 |
| Principal investigator 1 | Eli Lilly and Company | $482.25 | 10/27/2025 | Non-covered Recipient Entity RENSTAR INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187888228 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,500.00 | 10/21/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223287147 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,122.11 | 10/21/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287151 |
| Principal investigator 1 | Incyte Corporation | $2,825.00 | 10/20/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582103 |
| Principal investigator 1 | Incyte Corporation | $294.80 | 10/20/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582110 |
| Principal investigator 1 | ABBVIE INC. | $102.60 | 10/14/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202516713 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,717.00 | 10/13/2025 | Non-covered Recipient Entity RENSTAR | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | No dispute reported | 06/30/2026 | 1246434163 |
| Principal investigator 1 | ABBVIE INC. | $7,760.76 | 10/09/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515915 |
| Principal investigator 1 | Incyte Corporation | $2,489.00 | 10/08/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582074 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,600.00 | 10/07/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286421 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $250.00 | 10/07/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223286423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 10/06/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394558 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,881.70 | 10/01/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286079 |
| Principal investigator 1 | ABBVIE INC. | $1,100.00 | 09/23/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202511902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,526.00 | 09/22/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394517 |
| Principal investigator 1 | ABBVIE INC. | $255.69 | 09/18/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202511494 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,450.00 | 09/18/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285700 |
| Principal investigator 1 | Incyte Corporation | $117.00 | 09/17/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581995 |
| Principal investigator 1 | Incyte Corporation | $89.00 | 09/17/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582002 |
| Principal investigator 1 | Incyte Corporation | $160.00 | 09/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581989 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 09/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581999 |
| Principal investigator 1 | Incyte Corporation | $800.00 | 09/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582010 |
| Principal investigator 1 | Incyte Corporation | $1,100.00 | 09/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582044 |
| Principal investigator 1 | ABBVIE INC. | $1,100.00 | 09/11/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202510698 |
| Principal investigator 1 | Incyte Corporation | $1,638.40 | 09/10/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581971 |
| Principal investigator 1 | Incyte Corporation | $1,945.00 | 09/10/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 09/08/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394523 |
| Principal investigator 1 | ABBVIE INC. | $6,210.56 | 09/04/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509378 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 09/04/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394491 |
| Principal investigator 1 | Incyte Corporation | $622.70 | 09/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582031 |
| Principal investigator 1 | Incyte Corporation | $591.30 | 09/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582033 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 09/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582038 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,098.45 | 09/02/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284779 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,550.00 | 09/01/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394528 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 08/26/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505793 |
| Principal investigator 1 | ABBVIE INC. | $3,065.00 | 08/26/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,456.00 | 08/25/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394456 |
| Principal investigator 1 | ABBVIE INC. | $2,750.00 | 08/22/2025 | Non-covered Recipient Entity RENSTAR LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202505605 |
| Principal investigator 1 | ABBVIE INC. | $5,991.00 | 08/22/2025 | Non-covered Recipient Entity RENSTAR LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202505607 |
| Principal investigator 1 | ABBVIE INC. | $2,200.00 | 08/22/2025 | Non-covered Recipient Entity RENSTAR LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202505613 |
| Principal investigator 1 | Incyte Corporation | $1,584.90 | 08/20/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581962 |
| Principal investigator 1 | Incyte Corporation | $1,761.00 | 08/20/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581967 |
| Principal investigator 1 | ABBVIE INC. | $1,100.00 | 08/12/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202504247 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $850.00 | 08/12/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284103 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 08/12/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284105 |
| Principal investigator 1 | Eli Lilly and Company | $5,767.53 | 08/08/2025 | Non-covered Recipient Entity RENSTAR INC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187888400 |
| Principal investigator 1 | ABBVIE INC. | $29,872.91 | 08/06/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502795 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 08/06/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582028 |
| Principal investigator 1 | ABBVIE INC. | $4,572.25 | 08/05/2025 | Non-covered Recipient Entity RENSTAR LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202501526 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 08/04/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581985 |
| Principal investigator 1 | Incyte Corporation | $1,735.65 | 08/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,728.00 | 08/01/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394479 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,736.65 | 08/01/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283733 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,159.24 | 08/01/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,615.00 | 07/21/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394467 |
| Principal investigator 1 | Incyte Corporation | $1,672.95 | 07/18/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582041 |
| Principal investigator 1 | Incyte Corporation | $39.00 | 07/09/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581957 |
| Principal investigator 1 | Incyte Corporation | $2,620.00 | 07/09/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581977 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 07/08/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202497388 |
| Principal investigator 1 | ABBVIE INC. | $10,140.28 | 07/02/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496241 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 07/02/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496243 |
| Principal investigator 1 | Incyte Corporation | $129.44 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582006 |
| Principal investigator 1 | Incyte Corporation | $206.10 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582015 |
| Principal investigator 1 | Incyte Corporation | $26.50 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582017 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582021 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582024 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582048 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582051 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 07/01/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240582055 |
| Principal investigator 1 | Janssen Research & Development, LLC | $192.00 | 06/30/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394511 |
| Principal investigator 1 | Incyte Corporation | $1,808.80 | 06/25/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,100.00 | 06/23/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394473 |
| Principal investigator 1 | Incyte Corporation | $1,644.30 | 06/11/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581882 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 06/11/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581953 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $28,923.42 | 06/05/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280798 |
| Principal investigator 1 | ABBVIE INC. | $2,111.50 | 06/03/2025 | Non-covered Recipient Entity RENSTAR LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202489137 |
| Principal investigator 1 | ABBVIE INC. | $5,167.61 | 06/03/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489139 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581877 |
| Principal investigator 1 | Incyte Corporation | $249.08 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581889 |
| Principal investigator 1 | Incyte Corporation | $295.65 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581893 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581900 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581908 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581944 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581949 |
| Principal investigator 1 | Eli Lilly and Company | $97,460.95 | 06/02/2025 | Non-covered Recipient Entity RENSTAR INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187889124 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 05/29/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,234.00 | 05/26/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394535 |
| Principal investigator 1 | Incyte Corporation | $2,825.00 | 05/21/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581834 |
| Principal investigator 1 | Incyte Corporation | $1,904.00 | 05/21/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581837 |
| Principal investigator 1 | Incyte Corporation | $1,436.50 | 05/21/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581937 |
| Principal investigator 1 | ABBVIE INC. | $11,287.72 | 05/07/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482451 |
| Principal investigator 1 | Incyte Corporation | $1,937.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581808 |
| Principal investigator 1 | Incyte Corporation | $150.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581823 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581840 |
| Principal investigator 1 | Incyte Corporation | $1,088.10 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581843 |
| Principal investigator 1 | Incyte Corporation | $459.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581847 |
| Principal investigator 1 | Incyte Corporation | $276.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581852 |
| Principal investigator 1 | Incyte Corporation | $78.20 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581863 |
| Principal investigator 1 | Incyte Corporation | $1.86 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581896 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581904 |
| Principal investigator 1 | Incyte Corporation | $103.05 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581913 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581918 |
| Principal investigator 1 | Incyte Corporation | $56.73 | 05/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581933 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15,225.00 | 05/02/2025 | Non-covered Recipient Entity RENSTAR | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | No dispute reported | 06/30/2026 | 1246434154 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $842.40 | 05/01/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278770 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,248.00 | 04/28/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394499 |
| Principal investigator 1 | Incyte Corporation | $130.00 | 04/25/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581825 |
| Principal investigator 1 | Incyte Corporation | $490.00 | 04/25/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581830 |
| Principal investigator 1 | Eli Lilly and Company | $4,044.08 | 04/23/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187890614 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 04/23/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581804 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,000.00 | 04/18/2025 | Non-covered Recipient Entity RENSTAR | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | No dispute reported | 06/30/2026 | 1246434159 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,350.00 | 04/11/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394462 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 04/10/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277816 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $26,739.11 | 04/10/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277824 |
| Principal investigator 1 | Incyte Corporation | $2,620.00 | 04/09/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581813 |
| Principal investigator 1 | Incyte Corporation | $1,513.30 | 04/09/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581921 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 04/09/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581925 |
| Principal investigator 1 | Incyte Corporation | $4,050.00 | 04/07/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581800 |
| Principal investigator 1 | Incyte Corporation | $800.00 | 04/07/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581868 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 04/07/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581885 |
| Principal investigator 1 | Incyte Corporation | $550.00 | 04/07/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581929 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 04/07/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581941 |
| Principal investigator 1 | ABBVIE INC. | $6,464.40 | 04/03/2025 | Non-covered Recipient Entity RENSTAR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202472786 |
| Principal investigator 1 | Incyte Corporation | $1,672.95 | 04/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581817 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 04/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581859 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581873 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,696.30 | 03/25/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277019 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 03/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581559 |
| Principal investigator 1 | Incyte Corporation | $1,875.15 | 03/12/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581575 |
| Principal investigator 1 | ABBVIE INC. | $14,959.54 | 03/07/2025 | Non-covered Recipient Entity RENSTAR LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460889 |
| Principal investigator 1 | ABBVIE INC. | $1,826.65 | 03/07/2025 | Non-covered Recipient Entity RENSTAR LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202460893 |
| Principal investigator 1 | Eli Lilly and Company | $27,125.11 | 03/06/2025 | Non-covered Recipient Entity RENSTAR INC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187890374 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581651 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581655 |
| Principal investigator 1 | Incyte Corporation | $236.52 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581660 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581664 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581669 |
| Principal investigator 1 | Incyte Corporation | $622.70 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581671 |
| Principal investigator 1 | Incyte Corporation | $6.36 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581675 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581682 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581685 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581691 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581695 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581699 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581703 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581706 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581711 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581754 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581759 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581762 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581766 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581770 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581775 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581779 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,124.00 | 03/03/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394449 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $38,561.46 | 02/25/2025 | Non-covered Recipient Entity RENSTAR LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275531 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,735.48 | 02/20/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275427 |
| Principal investigator 1 | Incyte Corporation | $2,070.00 | 02/10/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581523 |
| Principal investigator 1 | Incyte Corporation | $1,926.00 | 02/10/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581527 |
| Principal investigator 1 | Incyte Corporation | $1,535.85 | 02/10/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581715 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,328.00 | 02/07/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175394546 |
| Principal investigator 1 | ABBVIE INC. | $1,644.50 | 02/06/2025 | Non-covered Recipient Entity RENSTAR LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202447417 |
| Principal investigator 1 | ABBVIE INC. | $14,895.24 | 02/06/2025 | Non-covered Recipient Entity RENSTAR LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447421 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,044.66 | 02/04/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274751 |
| Principal investigator 1 | Eli Lilly and Company | $3,191.10 | 01/27/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187890378 |
| Principal investigator 1 | Incyte Corporation | $2,741.50 | 01/27/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581543 |
| Principal investigator 1 | Incyte Corporation | $1,904.00 | 01/27/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581599 |
| Principal investigator 1 | Eli Lilly and Company | $83,819.00 | 01/21/2025 | Non-covered Recipient Entity RENSTAR INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187889956 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,100.00 | 01/21/2025 | Non-covered Recipient Entity Renstar Llc Renstar Medical Research | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226084667 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,470.00 | 01/21/2025 | Non-covered Recipient Entity Renstar Llc Renstar Medical Research | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226084671 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,413.00 | 01/21/2025 | Non-covered Recipient Entity Renstar Llc Renstar Medical Research | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226084674 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32.00 | 01/16/2025 | Non-covered Recipient Entity RENSTAR LLC | A Phase 2a2b Multi Center Randomized Placebo and Active Comparator controlled Double Blind Dose ranging Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa. | No dispute reported | 06/30/2026 | 1175394504 |
| Principal investigator 1 | Incyte Corporation | $1,407.30 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581531 |
| Principal investigator 1 | Incyte Corporation | $1,761.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581536 |
| Principal investigator 1 | Incyte Corporation | $2,828.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581540 |
| Principal investigator 1 | Incyte Corporation | $619.05 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581546 |
| Principal investigator 1 | Incyte Corporation | $1,632.70 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581550 |
| Principal investigator 1 | Incyte Corporation | $1,966.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581555 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581609 |
| Principal investigator 1 | Incyte Corporation | $1,827.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581613 |
| Principal investigator 1 | Incyte Corporation | $1,761.00 | 01/15/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581747 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,291.36 | 01/07/2025 | Non-covered Recipient Entity RENSTAR LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273683 |
| Principal investigator 1 | ABBVIE INC. | $2,914.85 | 01/02/2025 | Non-covered Recipient Entity RENSTAR LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202433941 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581563 |
| Principal investigator 1 | Incyte Corporation | $169.60 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581567 |
| Principal investigator 1 | Incyte Corporation | $307.40 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581571 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581578 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581581 |
| Principal investigator 1 | Incyte Corporation | $48.42 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581584 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581589 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581595 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581602 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581606 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581616 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581619 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581624 |
| Principal investigator 1 | Incyte Corporation | $35.02 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581628 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581631 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581635 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581638 |
| Principal investigator 1 | Incyte Corporation | $4.12 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581643 |
| Principal investigator 1 | Incyte Corporation | $4.12 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581647 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581679 |
| Principal investigator 1 | Incyte Corporation | $106.00 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581718 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581722 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581726 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581729 |
| Principal investigator 1 | Incyte Corporation | $169.60 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581734 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581739 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581743 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581750 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581784 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581787 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581792 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH OCALA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240581796 |